業務更新 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 China Wacan Group Company Limited 中國網成集團股份有限公司 （前稱China Wacan Group Company Limited中國網成集團有限公司） （於開曼群島註冊成立之有限公司） （股份代號: 1920) 自願公告 業務更新 本 公 告 乃 為 中 國 網 成 集 團 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱 為「本 集 團」）刊 發 的 自 願 公 告，以 將 本 集 團 業 務 發 展 之 最 新 消 息 告 知 本 公 司 股 東 及 潛 在投資者。 中國網成集團股份有限公司 董事局主席兼執行董事 周振林 香港，二零二五年八月八日 於 本 公 告 日 期，董 事 局 成 員 包 括 執 行 董 事 周 振 林 先 生、彭 運 英 女 士 及 郭 顯 教 先生以及獨立非執行董事丁昕女士、朱奇先生、張菱珂女士及林誠光教 ...

Group 1: Financial Performance - The company's revenue for the first half of 2025 is expected to grow by approximately 12% year-on-year, primarily due to a decline in sales of traditional Chinese medicine products compared to the previous year [1] - The net cash flow from operating activities is projected to be between 270 million and 290 million CNY, an improvement from 215.35 million CNY in the same period last year [3] Group 2: Cost Management - The company implements measures such as lean management, cost reduction, and comprehensive budget management to enhance expense control and improve efficiency [1] - Sales expense ratio is expected to fluctuate based on marketing strategies and product promotion, with a historical decline due to centralized procurement [2] Group 3: Market Expansion Strategies - The company plans to strengthen strategic partnerships with leading pharmacy chains and enhance patient education and promotion activities [4] - Digital marketing initiatives will be advanced through O2O strategies to capture the young consumer market [4] - Collaboration with Zhejiang University aims to develop innovative health products leveraging AI technology [5] Group 4: Research and Development - The company is focused on developing innovative traditional Chinese medicine, with several projects in clinical and preclinical stages [5] - Ongoing research includes secondary development of existing products and expanding indications for current medications [5]

Core Insights - The article discusses the recent entry of the education giant Fenbi into the food and beverage industry, specifically with the launch of a new tea drink store named "Jian Kang Xing Tea Drink" in Chengdu, focusing on health and wellness concepts [1][2][10] - Fenbi aims to position itself in the health sector, with plans to create affordable health products similar to Xiaomi, and has already established a nutrition health business called "Jian Kang Xing" [2][3] Company Developments - Fenbi opened its first "Jian Kang Xing Tea Drink" store in Chengdu, which features a two-story layout with tea drinks on the first floor and wellness services like massage on the second [2] - The tea drink store offers a variety of products, including seven major series with over 30 SKUs, focusing on health-oriented ingredients and pricing ranging from 15 to 30 yuan [3][6] - Fenbi previously launched two oatmeal baking stores in Jinan, emphasizing fresh and healthy products, with prices for baked goods ranging from 9 to 238 yuan [7][9] Industry Trends - The health food and beverage market is experiencing significant interest, with many companies entering the sector, particularly those from the pharmaceutical and health industries [10][11] - The health and wellness food market in China is projected to grow significantly, with total revenue expected to reach 9 trillion yuan by 2024, up from 8 trillion yuan in 2021, and potentially reaching 16 trillion yuan by 2030 [12]